Docebo Inc Ordinary Shares DCBO 深 沪
已收盘 11-07 16:00:00 美东时间
23.48
-0.880
-3.61%
华盛通- 最 高25.41
- 今 开24.52
- 成交量 23.76万股
- 最 低 22.79
- 昨 收 24.36
- 总市值 6.74亿
- 52周最高 50.80
- 市盈率 静 27.22
- 换手率 0.00%
- 52周最低 22.79
- 委 比 -22.70%
- 总股本 2872.32万
- 历史最高 92.75
- 量 比 2.30
- 振 幅 10.76%
- 历史最低 22.79
- 每 手 1
- 风险率 7.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Needham Maintains Buy on Docebo, Lowers Price Target to $38
Needham analyst Ryan MacDonald maintains Docebo (NASDAQ:DCBO) with a Buy and lowers the price target from $42 to $38.
今天 03:47
Earnings Scheduled For November 7, 2025
Companies Reporting Before The Bell • Kiora Pharmaceuticals (NASDAQ:KPRX) is pr...
11-07 19:11
Docebo Sees Q4 Sales $62.000M-$62.200M vs $61.163M Est
Docebo (NASDAQ:DCBO) sees Q4 sales of $62.000 million-$62.200 million vs $61.163 million analyst estimate.
11-07 19:02
Docebo Q3 Adj. EPS $0.34 Beats $0.33 Estimate, Sales $61.622M Beat $60.939M Estimate
Docebo (NASDAQ:DCBO) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.33 by 3.03 percent. This is a 25.93 percent increase over earnings of $0.27 per share from the same
11-07 19:01
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
CIBC Maintains Outperformer on Docebo, Lowers Price Target to $36
CIBC analyst Stephanie Price maintains Docebo (NASDAQ:DCBO) with a Outperformer and lowers the price target from $37 to $36.
10-30 04:18
美股大行评级 | 潜在涨幅1176.6%！Ascendiant Capital上调Society Pass目标价至18美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从15美元升至18美元；Ascendiant Capital：维持Surgepays"买入"评级，目标价从9美元升至9.5美元
10-06 08:35
TD Securities Reinstates Buy on Docebo, Announces $37 Price Target
TD Securities analyst Daniel Chan reinstates Docebo (NASDAQ:DCBO) with a Buy and announces $37 price target.
10-03 19:30
3 Bloated Software Stocks Screaming 'Short Me' At Insane Valuations
Affirm, AvePoint, and Docebo rank in the bottom 10% for value this week—see their percentile drop and what it signals for overvaluation.
09-09 20:26
